Compare OVBC & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | CNTN |
|---|---|---|
| Founded | 1872 | 2017 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 184.2M |
| IPO Year | 1996 | 2022 |
| Metric | OVBC | CNTN |
|---|---|---|
| Price | $45.07 | $3.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.6K | ★ 601.9K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.51 | $2.98 |
| 52 Week High | $47.12 | $5.27 |
| Indicator | OVBC | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 43.20 |
| Support Level | $34.69 | $3.07 |
| Resistance Level | $45.99 | $3.51 |
| Average True Range (ATR) | 0.76 | 0.23 |
| MACD | -0.26 | 0.01 |
| Stochastic Oscillator | 27.68 | 28.67 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.